Mumbai-based drug firm, Glenmark Pharmaceuticals, said on Tuesday it has launched a cancer treatment generic medication in the US market through its subsidiary, Glenmark Pharmaceuticals Inc., USA.
The medicine, Eribulin Mesylate Injection, is available in 1 mg/2 mL (0.5 mg/mL) single-dose vials, and will be distributed this month.
Glenmark’s product is therapeutically equivalent to the reference listed drug of Eisai, Inc.'s Halaven Injection, 1 mg/2 mL (0.5 mg/mL), it added.
"As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need," the company's President & Business Head, North America, Marc Kikuchi said.
Also Read: Indian pharma facility in China may break even at EBITDA level
According to IQVIA sales data for the 12-month period ended July 2025, the Halaven Injection, 1 mg/2 mL (0.5 mg/mL) market achieved annual sales of around USD 66.3 million.
Shares of Glenmark Pharma were trading 0.41 per cent lower at ₹1,920.20 apiece on the BSE.
Zydus launches influenza vaccine in India
Meanwhile, Zydus launched an influenza vaccine for flu protection in India, called the Vaxiflu trivalent influenza vaccine (TIV).
The firm, Zydus Lifesciences Ltd, announced on Tuesday that the trivalent influenza (flu) vaccine, called VaxiFlu, was introduced in India for the first time in line with global recommendations of the WHO.
The vaccine is recommended for individuals aged 6 months and above, and contains the latest, updated strains that were selected based on WHO's annual surveillance and recommendations.
“The strains ensure optimal protection and precision-targeted vaccination for the current season,” Zydus Lifesciences said in a regulatory filing.
Saying vaccine are a “critical part of preventive healthcare”, Zydus Lifesciences Managing Director, Sharvil Patel, said they believe in “aligning with global guidelines and enabling timely access to vaccines, as they are a critical part of preventive healthcare. We believe that this will significantly reduce vaccine-preventable diseases and related complications in high-risk groups.”
A contagious respiratory illness, flu is caused by influenza viruses that may spread through airborne respiratory droplets generated from coughing and sneezing or direct contact. The flu "remains a significant global health concern, causing 3-5 million cases of severe illness with 290,000 to 650,000 respiratory deaths annually", the company said.
The disease disproportionately affects vulnerable populations such as infants, the elderly, and individuals with chronic conditions, it added.
Follow us
